NCT04575363 RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
| NCT ID | NCT04575363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CHU de Reims |
| Condition | Pancreatic Ductal Adenocarcinoma (PDAC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2021-10-18 |
| Primary Completion | 2026-10-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2021-10-18 with a primary completion date of 2026-10-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity. Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.
Eligibility Criteria
inclusion criteria : * Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy * Adults (aged more than 18 years old) * Patients who have signed the informed consent form exclusion criteria : * Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment). * Minors * Patients for whom PDAC is not the retained diagnosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04575363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma (PDAC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04575363 currently recruiting?
Yes, NCT04575363 is actively recruiting participants. Contact the research team at joudart@chu-reims.fr for enrollment information.
Where is the NCT04575363 trial being conducted?
This trial is being conducted at Reims, France.
Who is sponsoring the NCT04575363 clinical trial?
NCT04575363 is sponsored by CHU de Reims. The trial plans to enroll 90 participants.